Neil Kumar - 16 Nov 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Chief Executive Officer, Director
Signature
/s/ Will Solis, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
16 Nov 2025
Transactions value $
-$2,181,243
Form type
4
Filing time
18 Nov 2025, 19:31:31 UTC
Previous filing
10 Nov 2025
Next filing
24 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kumar Neil Chief Executive Officer, Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 18 Nov 2025 0001742485

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +33.5K +15.04% 257K 16 Nov 2025 Direct F1
transaction BBIO Common Stock Options Exercise +19.6K +7.64% 276K 16 Nov 2025 Direct F1
transaction BBIO Common Stock Options Exercise +11.6K +4.18% 288K 16 Nov 2025 Direct F1
transaction BBIO Common Stock Tax liability -$2.18M -32.9K -11.42% $66.39 255K 16 Nov 2025 Direct F2
holding BBIO Common Stock 796K 16 Nov 2025 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. F3
holding BBIO Common Stock 4.6M 16 Nov 2025 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -33.5K -16.67% $0.00 168K 16 Nov 2025 Common Stock 33.5K Direct F1, F4
transaction BBIO Restricted Stock Units Options Exercise $0 -19.6K -10% $0.00 176K 16 Nov 2025 Common Stock 19.6K Direct F1, F5
transaction BBIO Restricted Stock Units Options Exercise $0 -11.6K -7.14% $0.00 150K 16 Nov 2025 Common Stock 11.6K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F5 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F6 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.